Related references
Note: Only part of the references are listed.Synthesis, SAR, and Biological Evaluation of α-Sulfonylphosphonic Acids as Selective Matrix Metalloproteinase Inhibitors
Maria Teresa Rubino et al.
CHEMMEDCHEM (2009)
1-hydroxy-2-pyridinone-based MMP inhibitors: Synthesis and biological evaluation for the treatment of ischemic stroke
Yue-Mei Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Syntheses and in vitro evaluation of arylsulfone-based MMP inhibitors with heterocycle-derived zinc-binding groups (ZBGs)
Yue-Mei Zhang et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Zinc-binding groups modulate selective inhibition of MMPs
Arpita Agrawal et al.
CHEMMEDCHEM (2008)
Role of sulfonamide group in matrix metalloproteinase inhibitors
Xian-Chao Cheng et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Progress in the development of matrix metalloproteinase inhibitors
GuoGang Tu et al.
CURRENT MEDICINAL CHEMISTRY (2008)
Peptidyl 3-substituted 1-hydroxyureas as isosteric analogues of succinylhydroxamate MMP inhibitors
Cristina Campestre et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2008)
Collagenase-2 deficiency or inhibition impairs experimental autoimmune encephalomyelitis in mice
Alicia R. Folgueras et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy
R. G. G. Russell et al.
OSTEOPOROSIS INTERNATIONAL (2008)
The roles of proteolytic enzymes in the development of tumour-induced bone disease in breast and prostate cancer
Julia K. L. Woodward et al.
BONE (2007)
Bone metastasis: pathogenesis and therapeutic implications
Philippe Clezardin et al.
CLINICAL & EXPERIMENTAL METASTASIS (2007)
The design of inhibitors for medicinally relevant metalloproteins
Faith E. Jacobsen et al.
CHEMMEDCHEM (2007)
α-biphenylsulfonylamino 2-methylpropyl phosphonates:: Enantioselective synthesis and selective inhibition of MMPs
Alessandro Biasone et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2007)
Development and characterization of biphenylsulfonamides as novel inhibitors of bone resorption
Iain R. Greig et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Novel therapeutic agents for bone resorption. Part 1. Synthesis and protonation thermodynamics of poly(amido-amine)s containing bis-phosphonate residues
Mario Casolaro et al.
BIOMACROMOLECULES (2006)
Extra precision glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes
Richard A. Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates
G Pochetti et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
N-hydroxyurea as zinc binding group in matrix metalloproteinase inhibition: Mode of binding in a complex with MMP-8
C Campestre et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2006)
Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions
Samuel Varghese
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Potent, selective pyrone-based inhibitors of stromelysin-1
DT Puerta et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
Synthesis and evaluation of new tripeptide phosphonate inhibitors of MMP-8 and MMP-2
M Agamennone et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2005)
Recent developments in the design of specific matrix metalloproteinase inhibitors aided by structural and computational studies
BG Rao
CURRENT PHARMACEUTICAL DESIGN (2005)
Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy
RA Friesner et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
The Zn2+ salt of pamidronate:: a role for water in the metal-cation binding properties of bisphosphonates
D Fernández et al.
ACTA CRYSTALLOGRAPHICA SECTION C-CRYSTAL STRUCTURE COMMUNICATIONS (2004)
New beginnings for matrix metalloproteinase inhibitors: Identification of high-affinity zinc-binding groups
DT Puerta et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2004)
Quest for selectivity in inhibition of matrix metalloproteinases
S Brown et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2004)
In vitro and in vivo antitumor effects of bisphosphonates
P Clezardin et al.
CURRENT MEDICINAL CHEMISTRY (2003)
NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability
PJ Hajduk et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Highly potent geminal bisphosphonates.: From pamidronate disodium (Aredia) to zoledronic acid (Zometa)
L Widler et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor
S Rowsell et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20), but not urokinase-type plasminogen activator, and diminish invasion and migration of human malignant and endothelial cell lines
P Heikkila et al.
ANTI-CANCER DRUGS (2002)
A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice
J Lee et al.
EUROPEAN JOURNAL OF CANCER (2001)
Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts
S Saad et al.
BREAST CANCER RESEARCH AND TREATMENT (2000)
The Protein Data Bank
HM Berman et al.
NUCLEIC ACIDS RESEARCH (2000)
Share Paper
